Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001929
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Treatment of Parkinsons Disease With Eliprodil
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
NMDA-Receptor Blockade With Eliprodil in Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2000-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with Parkinsons disease are missing the chemical neurotransmitter dopamine This occurs as a result of destructive changes in an area of the brain responsible for making dopamine the basal ganglia Patients with the disease experience rigid muscles stooped posture and a shuffling-type walk gait
In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinsons Disease Eliprodil works by blocking special receptors NMDA that are associated with the symptoms of Parkinsons Disease
In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinsons Disease Eliprodil works by blocking special receptors NMDA that are associated with the symptoms of Parkinsons Disease
Detailed Description:
The objectives of this study are to evaluate the acute effects of the NR2B subtype-selective NMDA antagonist eliprodil on levodopa-associated motor response complications in patients with advanced Parkinsons Disease PD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 99-N-0078 | None | None | None |